<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020864</url>
  </required_header>
  <id_info>
    <org_study_id>09.08</org_study_id>
    <nct_id>NCT01020864</nct_id>
  </id_info>
  <brief_title>Cetuximab in Combination With Chemotherapy for Patients With Head and Neck Cancer</brief_title>
  <acronym>CECAVI</acronym>
  <official_title>Phase II Trial of Cetuximab in Combination With Chemotherapy (Carboplatin and Navelbine) for Patients With Platinum-resistant Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Pfeiffer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open, multicenter phase II study. The purpose is to demonstrate the efficacy of
      cetuximab in combination with carboplatin and vinorelbine as second line treatment in
      patients with recurrent or metastatic head and neck cancer who have progressed during or
      after treatment with first line cisplatinum.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between response and evolvement in tumor biology markers.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with Cetuximab, Carboplatin and Vinorelbine i.v. day 1, every 2nd week.
Patients will be treated until progression and/or in case of unacceptable toxicity or if the patient wishes to stop treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab 500 mg/m² i.v. day 1, every 2nd week</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC = 3 i.v. day 1, every 21nd week</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>Vinorelbine 25 mg/m² i.v. day 1, every 2nd week</description>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified squamous cell carcinoma of the head and neck where curatively
             intended local treatment is not possible.

          -  Measurable or non-measurable disease.

          -  Disease progression during or after first line palliative chemotherapy with
             cisplatinum or patients with recurrence &lt; 6 months after primary concomitant
             chemo-radiotherapy with cisplatinum.

          -  WHO Performance Status 0-2.

          -  Age ≥ 18 years.

          -  Neutrophil count (ANC) ≥ 1.5 x 10^9/l and platelets ≥ 100 x 10^9/l.

          -  Normal liver function with bilirubin &lt; 1.5 x UNL (Upper Normal Limit), no UNL for ALAT
             with liver metastases.

          -  Creatinin clearance ≥ 50 ml/min.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Other active malignant disease.

          -  Patients who are considered unable to follow the treatment plan or follow-up visits.

          -  Other serious disease (e.g. severe heart disease, myocardial infarction (MI) within 1
             year, active infection).

          -  Any condition or treatment which after the opinion of the investigator may expose the
             patient to a risk or may influence the purpose of the trial.

          -  Pregnant or lactating women.

          -  Known hypersensitivity towards one or more of the components of the treatment.

          -  Prior treatment with either cetuximab or other inhibitors of EGFR.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Pfeiffer, Professor, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jorgen Johansen, MD, PhD</last_name>
    <phone>+45 6541 4568</phone>
    <email>jorgen.johansen@ouh.regionsyddanmark.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per Pfeiffer, Professor, MD, PhD</last_name>
    <phone>+45 6541 2921</phone>
    <email>per.pfeiffer@ouh.regionsyddanmark.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Oncology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorgen Johansen, MD, PhD</last_name>
      <phone>+45 6541 4568</phone>
      <email>jorgen.johansen@ouh.regionsyddanmark.dk</email>
    </contact>
    <investigator>
      <last_name>Jorgen Johansen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2009</study_first_submitted>
  <study_first_submitted_qc>November 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2009</study_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Per Pfeiffer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Platinum-resistent head and neck cancer</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Navelbine</keyword>
  <keyword>Phase II trial</keyword>
  <keyword>Combination chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

